Browse by category

Fractyl gains US$100 million financing to expand clinical development programs for T2DM

Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...

Fractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing)...

Fractyl Laboratories has announced the enrolment of the first patient in a pivotal clinical trial of Revita DMR (duodenal mucosal...

Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a...